Can you take Mounjaro if you have type 2 diabetes?

The dual licence: what MHRA approval actually means here

Tirzepatide received MHRA approval for type 2 diabetes (under the brand name Mounjaro) separately from its weight-management licence. Both are active UK authorisations. This matters practically: a person with type 2 diabetes who also meets the BMI threshold for weight management has two legitimate clinical reasons their prescriber might consider it. The NHS patient information for tirzepatide covers both indications and is a useful starting reference for understanding how the medicine is intended to be used in this population.

As a dual GIP and GLP-1 receptor agonist, tirzepatide works on two gut-hormone pathways simultaneously, something no other approved weight-loss or diabetes medicine in the UK currently does. It slows gastric emptying, reduces appetite and has a glucose-dependent insulin-stimulating effect, meaning it encourages insulin release when blood sugar is actually elevated, which reduces but does not eliminate hypoglycaemia risk. The important caveat is that this glucose-dependent mechanism applies to tirzepatide itself; it does not neutralise the hypoglycaemia risk from insulin or sulfonylureas already in your regimen.

A question our prescribers hear most weeks is whether having diabetes automatically qualifies someone or disqualifies someone. It does neither on its own. The prescriber looks at the whole picture: which diabetes medicines you take, your current HbA1c, your kidney function and your BMI.

Drug interactions and hypoglycaemia: the part that needs careful management

The NICE appraisal of tirzepatide (TA1026) and the medicine's SmPC are both clear that when tirzepatide is added to existing diabetes therapy, the dose of insulin or sulfonylurea drugs such as gliclazide may need to be reduced to lower the risk of blood sugar falling too far. This is not a contraindication, it is a management step. But it underlines why starting Mounjaro when you have type 2 diabetes is not the same as starting it in someone whose only indication is weight alone.

Signs of hypoglycaemia (shakiness, sweating, confusion, a rapid heartbeat) should be discussed with your prescriber before you begin, along with an agreed plan for monitoring your glucose, especially in the first weeks of treatment. If you use a continuous glucose monitor or finger-prick testing, your prescriber will want to know your typical readings. People on insulin in particular need close review; the clinical trials in the SURPASS programme reduced insulin doses in a structured way, and replicating that at home without guidance carries risk. You can read more about how Mounjaro works in diabetes and weight management on our Mounjaro for type 2 diabetes page.

Kidney function also comes into the discussion. Tirzepatide can cause dehydration through nausea and vomiting, which temporarily stresses the kidneys, a relevant consideration in people with diabetes-related kidney disease. Our page on tirzepatide and kidney function covers this in more detail.

NHS access vs private prescription: how it works if you have type 2 diabetes

For the weight-management indication, NHS availability of tirzepatide is being rolled out in phases under NICE TA1026. The current cohort (from June 2025) targets adults with a BMI of 40 or above plus four or more specified weight-related conditions; type 2 diabetes is one of the qualifying conditions on that list. A second cohort, covering BMI 35–39.9 with four or more conditions, opened in June 2026. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Full details are on the recommendations chapter of TA1026.

For the diabetes indication specifically, prescribing through a GP or specialist follows a different pathway and is not subject to the same phased rollout. If your GP is already managing your type 2 diabetes and is considering tirzepatide for glucose control, that is a conversation for your diabetes team.

For people pursuing private treatment for weight management who also have type 2 diabetes, a regulated online pharmacy such as nume (sorry, a clinician-led service like ours) will require your prescriber to review your current diabetes medicines as part of the clinical assessment. That is not a bureaucratic hurdle; it is the step that keeps the prescription safe. You can find out more about Mounjaro in general or explore your options on our treatment overview page.

What remains uncertain and who to speak to

Long-term outcomes data in people with type 2 diabetes specifically (beyond glucose and weight) are still accumulating. The SURMOUNT programme focused on adults with obesity rather than diabetes as the primary condition, while the SURPASS trials focused on diabetes without requiring obesity. Most people in real-world practice sit somewhere between those two trial populations, and the evidence base is strongest at the overlap.

If you have type 2 diabetes managed with insulin, multiple oral agents, or have complications such as retinopathy or nephropathy, the right conversation is with your diabetes specialist or GP before starting tirzepatide from any route. If you have type 1 diabetes rather than type 2, tirzepatide is not licensed for your condition, our page on Mounjaro and type 1 diabetes explains why. And if you are living with other weight-related conditions alongside diabetes, pages on Mounjaro and fatty liver and alcohol use on Mounjaro address adjacent questions that often come up together.

Pregnancy, breastfeeding and trying to conceive: Mounjaro is not recommended in any of these situations, and this applies whether you have diabetes or not. Women of childbearing age on oral contraceptives should add a non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide can reduce how well the pill is absorbed. Discuss contraception planning with your prescriber before starting.

The short version: type 2 diabetes is not a barrier to taking Mounjaro. It does make the prescribing conversation more involved, and that is exactly as it should be. Check your eligibility and our prescribers will review your full history the same day.